FDA label b3c806ce-e121-47aa-e053-2995a90a27be

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

SPL set ID
cc04f1f5-23db-4286-b997-f720edecbe5d
SPL ID
b3c806ce-e121-47aa-e053-2995a90a27be
Version
8
Effective date
2020-11-10
Source export date
2026-08-01
Source partition
4
Source file
https://download.open.fda.gov/drug/label/drug-label-0004-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-08-01/f23e8214fa581dc87bce024b3f15739356a8bb6f9298e3d6be38c21c662a4211/drug-label-0004-of-0014.json.zip
Source manifest SHA-256
bdd1454d0606b622b70458a306b8a10d8a8787db06fd9f46e69c7f7a4524b630
Import run
20260801T225920Z
Imported at
2026-08-01 23:05:53

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings

WARNINGS Cardiac Conduction: Diltiazem prolongs AV node refractory periods without significantly prolonging sinus node recovery time, except in patients with sick sinus syndrome. This effect may rarely result in abnormally slow heart rates (particularly in patients with sick sinus syndrome) or second- or third-degree AV block (13 of 3290 patients or 0.40%). Concomitant use of diltiazem with beta-blockers or digitalis may result in additive effects on cardiac conduction. A patient with Prinzmetal’s angina developed periods of asystole (2 to 5 seconds) after a single dose of 60 mg of diltiazem (see ADVERSE REACTIONS ). Congestive Heart Failure: Although diltiazem has a negative inotropic effect in isolated animal tissue preparations, hemodynamic studies in humans with normal ventricular function have not shown a reduction in cardiac index nor consistent negative effects on contractility (dp/dt). An acute study of oral diltiazem in patients with impaired ventricular function (ejection fraction 24% ± 6%) showed improvement in indices of ventricular function without significant decrease in contractile function (dp/dt). Worsening of congestive heart failure has been reported in patients with preexisting impairment of ventricular function. Experience with the use of diltiazem hydrochloride in combination with beta-blockers in patients with impaired ventricular function is limited. Caution should be exercised when using this combination. Hypotension: Decreases in blood pressure associated with diltiazem therapy may occasionally result in symptomatic hypotension. Acute Hepatic Injury: Mild elevations of transaminases with and without concomitant elevation in alkaline phosphatase and bilirubin have been observed in clinical studies. Such elevations were usually transient and frequently resolved even with continued diltiazem treatment. In rare instances, significant elevations in enzymes such as alkaline phosphatase, LDH, SGOT, SGPT, and other phenomena consistent with acute hepatic injury have been noted. These reactions tended to occur early after therapy initiation (1 to 8 weeks) and have been reversible upon discontinuation of drug therapy. The relationship to diltiazem is uncertain in some cases, but probable in some (see PRECAUTIONS ).

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

ADVERSE REACTIONS Serious adverse reactions have been rare in studies carried out to date, but it should be recognized that patients with impaired ventricular function and cardiac conduction abnormalities have usually been excluded from these studies. The following table presents the most common adverse reactions reported in placebo-controlled angina and hypertension trials in patients receiving diltiazem hydrochloride extended-release capsules up to 360 mg with rates in placebo patients shown for comparison. DILTIAZEM HYDROCHLORIDE EXTENDED-RELEASE CAPSULE PLACEBO-CONTROLLED ANGINA ANDHYPERTENSION TRIALS COMBINED Diltiazem Hydrochloride Extended-Release Capsules Placebo Adverse Reaction n=607 n=301 Headache 5.4% 5.0% Dizziness 3.0% 3.0% Bradycardia 3.3% 1.3% AV Block First Degree 3.3% 0.0% Edema 2.6% 1.3% ECG Abnormality 1.6% 2.3% Asthenia 1.8% 1.7% In clinical trials of diltiazem hydrochloride extended-release capsules, diltiazem hydrochloride tablets, and diltiazem hydrochloride sustained-release capsules involving over 3200 patients, the most common events (ie, greater than 1%) were edema (4.6%), headache (4.6%), dizziness (3.5%), asthenia (2.6%), first degree AV block (2.4%), bradycardia (1.7%), flushing (1.4%), nausea (1.4%), and rash (1.2%). In addition, the following events were reported infrequently (less than 1%) in angina or hypertension trials: Cardiovascular: Angina, arrhythmia, AV block (second- or third-degree), bundle branch block, congestive heart failure, ECG abnormalities, hypotension, palpitations, syncope, tachycardia, ventricular extrasystoles. Nervous System: Abnormal dreams, amnesia, depression, gait abnormality, hallucinations, insomnia, nervousness, paresthesia, personality change, somnolence, tinnitus, tremor. Gastrointestinal: Anorexia, constipation, diarrhea, dry mouth, dysgeusia, dyspepsia, mild elevations of SGOT, SGPT, LDH, and alkaline phosphatase (see WARNINGS, Acute Hepatic Injury), thirst, vomiting, weight increase Dermatological: Petechiae, photosensitivity, pruritus, urticaria. Other: Amblyopia, CPK increase, dyspnea, epistaxis, eye irritation, hyperglycemia, hyperuricemia, impotence, muscle cramps, nasal congestion, nocturia, osteoarticular pain, polyuria, sexual difficulties. The following postmarketing events have been reported infrequently in patients receiving diltiazem hydrochloride: acute generalized exanthematous pustulosis, allergic reactions, alopecia, angioedema (including facial or periorbital edema), asystole, erythema multiforme (including Stevens-Johnson syndrome, toxic epidermal necrolysis), exfoliative dermatitis, extrapyramidal symptoms, gingival hyperplasia, hemolytic anemia, increased bleeding time, leukopenia, photosensitivity (including lichenoid keratosis and hyperpigmentation at sun-exposed skin areas), purpura, retinopathy, myopathy and thrombocytopenia. In addition, events such as myocardial infarction have been observed which are not readily distinguishable from the natural history of the disease in these patients. A number of well-documented cases of generalized rash, some characterized as leukocytoclastic vasculitis, have been reported. However, a definitive cause and effect relationship between these events and diltiazem therapy is yet to be established.

adverse reactions table

<table><caption> DILTIAZEM HYDROCHLORIDE EXTENDED-RELEASE CAPSULE PLACEBO-CONTROLLED ANGINA ANDHYPERTENSION TRIALS COMBINED</caption><col/><col/><col/><thead><tr><td valign="top"> </td><td align="center" valign="top"> <content styleCode="bold">Diltiazem</content></td><td align="center" valign="top"> </td></tr><tr><td valign="top"> </td><td align="center" valign="top"> <content styleCode="bold">Hydrochloride</content></td><td align="center" valign="top"> </td></tr><tr><td valign="top"> </td><td align="center" valign="top"> <content styleCode="bold">Extended-Release Capsules </content></td><td align="center" valign="top"> <content styleCode="bold">Placebo</content></td></tr><tr><td valign="top"> <content styleCode="bold">Adverse Reaction</content></td><td align="center" valign="top"> <content styleCode="bold">n=607</content></td><td align="center" valign="top"> <content styleCode="bold">n=301</content></td></tr></thead><tbody><tr><td valign="top"> Headache</td><td align="center" valign="top"> 5.4%</td><td align="center" valign="top"> 5.0%</td></tr><tr><td valign="top"> Dizziness</td><td align="center" valign="top"> 3.0%</td><td align="center" valign="top"> 3.0%</td></tr><tr><td valign="top"> Bradycardia</td><td align="center" valign="top"> 3.3%</td><td align="center" valign="top"> 1.3%</td></tr><tr><td valign="top"> AV Block First Degree</td><td align="center" valign="top"> 3.3%</td><td align="center" valign="top"> 0.0%</td></tr><tr><td valign="top"> Edema</td><td align="center" valign="top"> 2.6%</td><td align="center" valign="top"> 1.3%</td></tr><tr><td valign="top"> ECG Abnormality</td><td align="center" valign="top"> 1.6%</td><td align="center" valign="top"> 2.3%</td></tr><tr><td valign="top"> Asthenia</td><td align="center" valign="top"> 1.8%</td><td align="center" valign="top"> 1.7%</td></tr></tbody></table>